Table 2. Results of CMR imaging during follow-up in patients with COVID-19 hospitalization and in the control group.
| Variable | N | COVID-19 (n = 95) | Control (n = 43) | P-value |
|---|---|---|---|---|
| LVEDV (ml/m2) | 138 | 77 (68–87) | 82 (76–91) | 0.02 |
| LVEF (%) | 138 | 60 (56–64) | 59 (58–63) | 1.00 |
| LV mass (g/m2) | 138 | 52 ± 11 | 52 ± 8 | 0.60 |
| Left ventricular WMA | 138 | 5 | 0 | 0.13 |
| RVEDV (ml/m2) | 138 | 79 ± 14 | 85 ± 15 | 0.03 |
| RVEF (%) | 138 | 58 (55–62) | 59 (55–61) | 0.93 |
| Right ventricular WMA | 138 | 2 | 0 | 0.34 |
| Left atrial area (cm/m2) | 138 | 11 ± 2 | 12 ± 2 | 0.03 |
| Right atrial area (cm/m2) | 138 | 10 (8–11) | 12 (10–13) | <0.001 |
| Left ventricular oedema | 138 | 0 (0%) | 0 (0%) | 1.00 |
| Abnormal rest perfusion | 136 | 1 (1%) | 0 (0%) | 0.49 |
| Late gadolinium enhancement | ||||
| Any LGE | 136 | 61 (66%) | 16 (37%) | <0.01 |
| Ischemic pattern | 136 | 7 (8%) | 1 (2%) | 0.13 |
| Myocarditis pattern | 136 | 27 (29%) | 4 (9%) | 0.01 |
Data are presented as number of patients (%) or mean ± SD, or median (interquartile range). LGE = late gadolinium enhancement; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; WMA = wall motion abnormality.